Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Erlotinib pharmacokinetics

Tan AR et al (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22 3080-3090... [Pg.241]

Hidalgo M et al (2003) Pharmacokinetics and pharmacodynamics maximizing the clinical potential of erlotinib (tarceva). Semin Oncol 30 25-33... [Pg.243]

Lu JF et al (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80 136-145... [Pg.243]

Rudin CM et al (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity J Clin Oncol 26 1119-1127... [Pg.245]

There was no change in the pharmacokinetics of gemcitabine or erlotinib on concurrent use in a phase 1 study... [Pg.629]

Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res (2006) 12, 2166-71. [Pg.629]

Li, L., Li, J., Khanna, M., et al. 2010. Ooddng small molecules to predicted off-targets of the cancer drug erlotinib leads to inhibitors of limg cancer cell proliferation with suitable in vitro pharmacokinetic properties. ACS Med. Chem. Lett. 1 229-233. [Pg.200]

See other pages where Erlotinib pharmacokinetics is mentioned: [Pg.530]    [Pg.97]    [Pg.100]    [Pg.319]    [Pg.209]    [Pg.218]    [Pg.628]    [Pg.430]   
See also in sourсe #XX -- [ Pg.1295 ]



SEARCH



Erlotinib

© 2024 chempedia.info